Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2007

View Archived Issues

PTP-1B inhibitors claimed in recent patent by Metabasis

Several series of protein kinase inhibitors claimed for the treatment of cancer

Eisai announces first quarter results

Curcumin reverses amyloid pathology in mouse model of Alzheimer's disease

Cholesterol biosynthesis inhibitor reduces amyloid-beta in vitro

Denufosol improves lung function in phase II cystic fibrosis study

First half 2007 results reported by sanofi-aventis

Urigen begins phase II study of URG-101 for PBS

Allos begins enrollment for phase I study of PDX with vitamin B12 and folic acid

CombinatoRx begins phase IIa study of CRx-401 for type 2 diabetes

Millennium begins phase II trial of Velcade for MM

Positive results for Neuraxon's phase I trial of NXN-188 for migraine

Accentia reports interim analysis of phase III trial of SinuNase for CS

GSK begins phase I trial of GSK-923295 for solid tumors

VGX begins IND-enabling preclinical toxicology studies of three product candidates

EKR acquires marketing rights to Pacira's DepoDur for postoperative pain

New recombinant neuregulin-1 ameliorates cardiac output in chronic heart failure

Noven acquisition of JDS Pharmaceuticals completed

Parion and Gilead to codevelop ENaC inhibitors for pulmonary diseases

Vion enrolls 85 elderly patients in pivotal phase II trial of Cloretazine for AML

European Commission grants Chelsea Therapeutics' droxidopa two orphan drug titles

EMEA recommends orphan drug status for Progen's PI-88 as it enters phase III trial

The MMRC and Proteolix start carfilzomib phase II clinical trial in multiple myeloma

Oncoscience completes enrollment in phase III brain cancer trial of nimotuzumab

Hedgehog signaling activators discovered with potential in neurodegenerative disorders

Novel, potent hydroxyhydantoin MMP inhibitors presented at ACS meeting

FDA approves Novartis' once-yearly Reclast for postmenopausal osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...